{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:24:54Z","timestamp":1790846694088,"version":"4.1.0"},"reference-count":14,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiol Drug Saf"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1002\/pds.3975","type":"journal-article","created":{"date-parts":[[2016,2,18]],"date-time":"2016-02-18T16:11:39Z","timestamp":1455811899000},"page":"413-421","source":"Crossref","is-referenced-by-count":2,"title":["Development and validation of an algorithm for identifying urinary retention in a cohort of patients with epilepsy in a large US administrative claims database"],"prefix":"10.1002","volume":"25","author":[{"given":"Scott C.","family":"Quinlan","sequence":"first","affiliation":[{"name":"HealthCore, Inc.; Wilmington DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy Y.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.; Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianna","family":"Ishihara","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline plc; Uxbridge Middlesex UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Irizarry","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline plc; Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal N.","family":"Holick","sequence":"additional","affiliation":[{"name":"HealthCore, Inc.; Wilmington DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.; Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,2,17]]},"reference":[{"key":"10.1002\/pds.3975-BIB0001|pds3975-cit-0001","first-page":"31","article-title":"The descriptive epidemiology of epilepsy-a review","volume":"85","author":"Banerjee","year":"2009","journal-title":"EpilepsyRes"},{"key":"10.1002\/pds.3975-BIB0002|pds3975-cit-0002","first-page":"409","article-title":"Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures","volume":"7","author":"Weisenberg","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1002\/pds.3975-BIB0003|pds3975-cit-0003","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1002\/pds.3975-BIB0004|pds3975-cit-0004","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1474-4422(07)70215-6","article-title":"Development of new antiepileptic drugs: challenges, incentives, and recent advances","volume":"6","author":"Perucca","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1002\/pds.3975-BIB0005|pds3975-cit-0005","first-page":"1","article-title":"Retigabine: chemical synthesis to clinical application","volume":"11","author":"Blackburn-Munro","year":"2005","journal-title":"CNSDrug Rev"},{"key":"10.1002\/pds.3975-BIB0006|pds3975-cit-0006","first-page":"73","article-title":"The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2\/3 subunits","volume":"282","author":"Rundfeldt","year":"2000","journal-title":"NeurosciLett"},{"key":"10.1002\/pds.3975-BIB0007|pds3975-cit-0007","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1124\/mol.58.3.591","article-title":"Retigabine, a novel anti-convulsant, enhances activation of KCNQ2\/Q3 potassium channels","volume":"58","author":"Wickenden","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1002\/pds.3975-BIB0008|pds3975-cit-0008","first-page":"1","article-title":"Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX)","volume":"83","author":"Bialer","year":"2009","journal-title":"EpilepsyRes"},{"key":"10.1002\/pds.3975-BIB0009|pds3975-cit-0009","first-page":"110","article-title":"Ezogabine 600 or 900\u2009mg\/day as adjunctive therapy in adults with partial-onset seizures","volume":"49","author":"Brodie","year":"2008","journal-title":"Epilepsia"},{"key":"10.1002\/pds.3975-BIB0010|pds3975-cit-0010","first-page":"112","article-title":"1200\u2009mg\/day ezogabine as adjunctive therapy in adults with refractory partial-onset seizures","volume":"49","author":"French","year":"2008","journal-title":"Epilepsia"},{"key":"10.1002\/pds.3975-BIB0011|pds3975-cit-0011","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/01.wnl.0000259034.45049.00","article-title":"Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures","volume":"68","author":"Porter","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/pds.3975-BIB0012|pds3975-cit-0012","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.eplepsyres.2012.03.010","article-title":"Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials","volume":"101","author":"Porter","year":"2012","journal-title":"Epilepsy Res"},{"key":"10.1002\/pds.3975-BIB0013|pds3975-cit-0013","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1528-1167.2012.03441.x","article-title":"The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels","volume":"53","author":"Brickel","year":"2012","journal-title":"Epilepsia"},{"key":"10.1002\/pds.3975-BIB0014|pds3975-cit-0014","first-page":"1","article-title":"Exceptions to the rule about non-differential misclassification","volume":"122","author":"Poole","year":"1985","journal-title":"Am J Epidemiol"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3975","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/pds.3975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T18:37:50Z","timestamp":1567622270000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/pds.3975"}},"subtitle":["A Claims-based Algorithm for Urinary Retention"],"short-title":[],"issued":{"date-parts":[[2016,2,17]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"URL":"https:\/\/doi.org\/10.1002\/pds.3975","archive":["Portico"],"relation":{},"ISSN":["1053-8569"],"issn-type":[{"value":"1053-8569","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2,17]]}}}